Nanobiotix S.A. - ADSs (NQ:NBTX)

Performance

52-Week Range 47.5% below 52-week high

29.99

18.5852W Low 57.1452W High

1 Week 12.1% below 1-week high

27.481W Low 34.111W High

Nanobiotix S.A. - ADSs (NBTX) traded between $18.58 and $57.14 over the past 52 weeks and last traded at $29.99, 47.5% below its 52-week high. Over the past week it ranged between $27.48 and $34.11.

Past 12 Months

-11.3%

+19.5%

-24.4%

-28.4%

+35.5%

+55.1%

1W -$3.81

1M +$4.89

3M -$9.68

6M -$11.87

YTD +$7.86

1Y +$10.66

NBTX was +55.1% over the past year, -28.4% over six months, +35.5% year to date, -11.3% in the last week.

12 Months vs Market

NBTX

+55.1%

DIA

+9.7%

SPY

+9.0%

QQQ

+5.8%

IWM

+12.5%

Over the past 12 months NBTX returned +55.1% versus DIA (Dow) +9.7%, SPY (S&P 500) +9.0%, QQQ (Nasdaq 100) +5.8% and IWM (Russell 2000) +12.5%.

Volume & Liquidity 2.39× 3-mo avg

Today 362,124 3-mo avg 151.3K

167.6K

138.3K

151.3K

125.6K

YTD

97.4K

89.1K

NBTX most recently traded 362,124 shares against a 3-month average daily volume of 151.3K.

More News

October 20, 2026

NANOBIOTIX Announces the Appointment of Arnd Christ as Chief Financial Officer

October 01, 2026

NANOBIOTIX Provides First Half 2026 Operational and Financial Update

September 24, 2026

September 22, 2026

NANOBIOTIX Announces Complete Full Cohort Phase 1 Results for JNJ-1900 (NBTXR3) in Inoperable, Recurrent Non-Small Cell Lung Cancer

September 14, 2026

NANOBIOTIX to Participate in the H.C. Wainwright 28th Annual Global Investment Conference

September 09, 2026

Johnson & Johnson Owns Stakes in 15 Stocks. Here's the Best of the Bunch. ↗

August 31, 2026

Via The Motley Fool

August 25, 2026

July 30, 2026

June 05, 2026

Nanobiotix Provides First Quarter 2026 Operational and Financial Update

June 02, 2026

Nanobiotix Joins the Euronext Tech Leaders Index

June 02, 2026

NANOBIOTIX Announces Closing of Global Offering

May 26, 2026

NANOBIOTIX Announces Full Exercise of Underwriters’ Over-Allotment Option, Bringing Gross Proceeds of Offering to Approximately $100 Million

May 22, 2026

Nanobiotix Announces Pricing of Oversubscribed €85m Global Offering

May 21, 2026

Nanobiotix Announces Trading Resumption of Its Ordinary Shares on Euronext Paris

May 21, 2026

Nanobiotix Announces Temporary Trading Halt of Its Ordinary Shares on Euronext Paris

May 21, 2026

Nanobiotix Announces Launch of Global Follow-On Offering

May 20, 2026

Nanobiotix Announces Presentation of Part 1 Data From a Randomized Phase 2 Clinical Trial Evaluating JNJ-1900 (NBTXR3) in Stage 3 Inoperable Lung Cancer

May 17, 2026

Nanobiotix Announces Protocol Amendment to Ongoing Global Phase 3 Head and Neck Cancer Study

May 04, 2026

Nanobiotix Announces New Preclinical Data Supporting Improved Systemic Bioavailability and Reduced Toxicity for LNP-Delivered DNA Immunotherapy After Pre-Treatment With Nanoprimer Technology

April 20, 2026

April 07, 2026

NANOBIOTIX Provides Business Update and Reports Full Year 2025 Financial Results

March 31, 2026